Doxorubicin Hydrochloride (as pegylated liposomal)

1. For the treatment of AIDS-related Kaposi’s sarcoma in patients with low CD4 (<200 CD4 lymphocytes/mm³) and diseases in mucosa, skin and internal organs.2. For treatment of advanced, recurrent, or metastatic ovarian cancer in women who have failed first-line platinum-based chemotherapy treatment.
3.As monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk.
4.In combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant.